AI 藥物開發商 Basecamp 完成1.4億美元融資後估值達8億美元

作者：普揚・辛格By Puyaan Singh

9月23日（路透社）— Basecamp Research 週三表示，該公司已在 C 輪募資中籌得1.4億美元，這輪融資使這家 AI 藥物開發商估值達8億美元。Sept 23 (Reuters) - Basecamp Research said on Wednesday it has raised $140 million in a Series C funding round that valued the AI-based drug developer at $800 million.

這輪募資獲得超額認購，由 S32 領投，參與投資者包括輝達（Nvidia）、Anthropic 旗下 Anthology Fund、Catalio Capital Management、北約創新基金（NATO Innovation Fund）、洛克斐勒基金會（Rockefeller Foundation）與 Singular 等。The oversubscribed round was led by S32, with participation from Nvidia, Anthropic's Anthology Fund, Catalio Capital Management, the NATO Innovation Fund, the Rockefeller Foundation and Singular, among other investors.

• Basecamp 於2024年10月完成 B 輪募資，籌得6000萬美元，該輪由 Singular 領投。• Basecamp raised $60 million in its Series B round in October 2024, led by Singular.

• 公司表示，將把最新資金用於訓練新一代 EDEN 生物基礎模型，並推動一系列由 AI 設計的療法邁向臨床開發。• The company said it would use the latest funding to train a new generation of its EDEN biological foundation models and move a pipeline of AI-designed therapies toward clinical development.

• 這家總部位於倫敦的公司初期將專注於可在體內重新編程病患細胞的療法。• The London-based company will initially focus on therapies that reprogram patients' cells inside the body.

• 公司表示，相較於其所稱目前每名病患費用達「數十萬美元」的現行療法，EDEN 技術可讓癌症與自體免疫疾病的細胞療法更能客製化，也更容易施用。• The company said its EDEN technology could make cell therapies more customizable and easier to administer for cancer and autoimmune diseases, compared to current treatments that it said cost "hundreds of thousands of dollars per patient".

• Basecamp 並表示，該公司已在多種類型的療法與疾病中展現強勁的臨床前結果，但未提供啟動臨床試驗的時程。• Basecamp added it had demonstrated strong preclinical results across several types of therapies and diseases, but did not provide a timeline for starting clinical trials.

• 公司表示，EDEN 是以 Basecamp 專有的基因組資料集訓練而成；該資料集透過30多個國家的合作關係建立，EDEN 可根據疾病相關資訊生成潛在候選藥物。• EDEN is trained on Basecamp's proprietary genomic dataset, assembled through partnerships in more than 30 countries, and can generate potential drug candidates based on information about a disease, the company said.

• 公司也任命 Biogen 前高階主管理查・皮爾斯（Richard Pearce）為首席商務長，以拓展其製藥業合作關係。• The company also appointed former Biogen executive Richard Pearce as chief business officer to expand its pharmaceutical partnerships.

（普揚・辛格班加羅爾報導；維傑・基肖爾編輯）(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)